

## 1 Suspect Screening, Prioritization, and Confirmation of 2 Environmental Chemicals in Maternal-Newborn Pairs from San 3 Francisco

4 Aolin Wang,<sup>+</sup> Dimitri Panagopoulos Abrahamsson,<sup>+</sup> Ting Jiang, Miaomiao Wang,  
5 Rachel Morello-Frosch, June-Soo Park, Marina Sirota, and Tracey J. Woodruff\*



Cite This: <https://dx.doi.org/10.1021/acs.est.0c05984>



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

6 **ABSTRACT:** Our proof-of-concept study develops a suspect  
7 screening workflow to identify and prioritize potentially ubiquitous  
8 chemical exposures in matched maternal/cord blood samples, a  
9 critical period of development for future health risks. We applied  
10 liquid chromatography–quadrupole time-of-flight tandem mass  
11 spectrometry (LC-QTOF/MS) to perform suspect screening for  
12 ~3500 industrial chemicals on pilot data from 30 paired maternal  
13 and cord serum samples ( $n = 60$ ). We matched 662 suspects in  
14 positive ionization mode and 788 in negative ionization mode (557  
15 unique formulas overall), and selected 208 of these for  
16 fragmentation analysis based on detection frequency, correlation  
17 in feature intensity between maternal and cord samples, and peak  
18 area differences by demographic characteristics. We tentatively  
19 identified 73 suspects through fragmentation spectra matching and confirmed 17 chemical features (15 unique compounds) using  
20 reference standards. We tentatively identified 55 compounds not previously reported in the literature, the majority which have  
21 limited to no information about their sources or uses. Examples include (i) 1-(1-acetyl-2,2,6,6-tetramethylpiperidin-4-yl)-3-  
22 dodecylpyrrolidine-2,5-dione (known high production volume chemical) (ii) methyl perfluoroundecanoate and 2-perfluorooctyl  
23 ethanoic acid (two PFAS compounds); and (iii) Sumilizer GA 80 (plasticizer). Thus, our workflow demonstrates an approach to  
24 evaluating the chemical exposome to identify and prioritize chemical exposures during a critical period of development.  
25 **KEYWORDS:** *suspect screening, exposome, high-throughput, maternal blood, cord blood, pregnancy, biomonitoring*



### 26 ■ INTRODUCTION

27 Prenatal exposure to environmental chemicals can lead to  
28 myriad health consequences throughout life.<sup>1–4</sup> Prior research  
29 using National Health and Nutrition Examination Survey  
30 (NHANES) data found that pregnant women in the U.S. are  
31 exposed to multiple different chemicals.<sup>5,6</sup> Most of these  
32 chemicals can cross the placenta into the fetal environment,<sup>7,8</sup>  
33 with sometimes higher exposure to the fetus compared to  
34 maternal blood measurements, such as mercury and poly-  
35 chlorinated biphenyls.<sup>4</sup> In a study of 65 pregnant women in  
36 San Francisco, we detected a median of ~25 chemicals in  
37 maternal serum (out of 59 compounds tested), of which ~80%  
38 were also detected in matched umbilical cord serum samples,  
39 with some compounds having higher concentrations than  
40 maternal levels.<sup>9</sup> Existing biomonitoring research mainly relies  
41 on targeted analytical methods that cover only a few hundred  
42 chemicals.<sup>6</sup> This is likely a small fraction of all the potential  
43 chemicals that humans are exposed to, as ~8000 chemicals are  
44 manufactured or imported in large volume (>25 000 lbs/year)  
45 in the U.S.,<sup>10</sup> and chemical production totals at least 9.5 trillion

pounds,<sup>10,11</sup> let alone the approximately 40 000 chemicals  
46 currently in commerce in the U.S.<sup>12</sup> A recent study reviewed  
47 over 700 chemicals from multiple chemical classes that have a  
48 high likelihood of exposure among mothers and children, have  
49 a potentially toxic structural moiety, but are not currently  
50 measured via biomonitoring or health effects in National  
51 Institutes of Health (NIH)'s Environmental influences on  
52 Child Health Outcomes (ECHO) initiative or NHANES.<sup>13</sup>  
53 The authors recommended 155 chemicals of high priority for  
54 future biomonitoring, suggesting an unmet need for character-  
55 izing exposures to these “known unknown” chemicals.  
56

Recent advancements in high-resolution mass spectrometry  
57 (HRMS) paired with novel computational and statistical  
58

Received: September 7, 2020

Revised: February 22, 2021

Accepted: February 22, 2021

59 approaches provide an opportunity for large-scale screening of  
60 chemicals from biological and environmental samples.<sup>14–17</sup> By  
61 leveraging the nontargeted chemical feature acquisition,  
62 suspect screening can efficiently identify chemicals of interest  
63 using HRMS and software-matching algorithms that map these  
64 features against user-defined chemical databases or existing  
65 chemical inventories.<sup>18</sup> This technology has gained increasing  
66 popularity in recent years as a new tool for environmental  
67 monitoring,<sup>19–22</sup> metabolite discovery,<sup>23,24</sup> and biomonitoring  
68 of industrial chemicals<sup>25,26</sup> to better characterize the  
69 chemosome,<sup>27</sup> the industrial chemical components of the  
70 human exposome.<sup>28</sup>

71 While there are numerous publications on HRMS in  
72 environmental monitoring and metabolite discovery, the  
73 application of this technique to biomonitoring of industrial  
74 chemicals remains limited. In a previous study, we leveraged  
75 this technology to identify novel chemicals never measured  
76 before in the blood of pregnant women,<sup>26</sup> and found that they  
77 are exposed to more chemicals than previously documented.  
78 As the first proof-of-concept study in applying suspect  
79 screening to detect chemicals in pregnant women's serum,  
80 we limited our search to a subset of environmental chemicals  
81 called environmental organic acids (EOAs), compounds with  
82 at least one ionizable proton, by using the negative ionization  
83 mode to optimize their detection.<sup>26</sup>

84 This paper builds upon our previous work<sup>26</sup> to demonstrate  
85 the application of a suspect screening method for character-  
86 izing exposure to a broader array of industrial chemicals in  
87 matched maternal and cord serum samples, a critical  
88 developmental period of health risk. We have developed and  
89 tested an analytical approach that uses HRMS to screen for  
90 multiple chemicals and a workflow to prioritize and identify  
91 ubiquitous endogenous chemicals that are differentially  
92 enriched in maternal/cord samples and/or across various  
93 demographic groups. Applying our approach to data from 30  
94 paired maternal and cord serum samples ( $N = 60$  total  
95 samples), we expand work in the field of suspect screening and  
96 nontargeted analysis of human blood samples in four ways: (1)  
97 using a chemical database of approximately 3500 high-  
98 production volume chemicals as well as chemicals of emerging  
99 concern including an expanded list of short-chain per- and  
100 polyfluoroalkyl substances;<sup>29</sup> (2) using both positive and  
101 negative ionization modes to facilitate detection of more  
102 chemical features; (3) evaluating cord serum matched to  
103 maternal serum allowing evaluation of differential enrichment  
104 of chemicals between the two; and (4) confirming chemical  
105 structures via matching of experimental MS/MS spectra  
106 against MS/MS spectra from existing reference libraries and  
107 analytical standards. Furthermore, to the best of our knowl-  
108 edge, this is the first study to characterize the chemical  
109 exposome to industrial chemicals in matched maternal and  
110 cord blood sample pairs using a suspect screening or a  
111 nontargeted analysis approach.

## 112 ■ MATERIALS AND METHODS

113 **Study Population and Sample Collection.** The study  
114 population is part of the Chemicals in Our Bodies 2 Study  
115 (CiOB2), which consists of women seeking prenatal and  
116 delivery care at the Zuckerberg San Francisco General Hospital  
117 and UCSF Mission Bay Medical Center.<sup>26</sup> From April 2, 2014,  
118 we enrolled women from an economically and ethnically  
119 diverse population (47% Latina, 37% non-Hispanic whites, and  
120 17% non-Hispanic Asians, Pacific Islanders, African Ameri-


cans) who were English or Spanish-speaking, aged 18 through 121  
40 years old, and had singleton pregnancies between 13 and 27 122  
weeks gestation (second trimester) at the time of recruitment. 123  
Paired maternal and cord blood samples were collected at 124  
delivery for chemical analysis from participants who agreed to 125  
have their samples banked and included in supplemental 126  
studies. Maternal blood was collected during labor and delivery 127  
and umbilical cord blood after delivery and prior to umbilical 128  
cord clamping whenever possible. Blood was collected in BD 129  
Vacutainer Plus Serum Tubes and stored at  $-80$  °C until 130  
analysis. We collected demographic information via inter- 131  
viewer-administered questionnaire and obtained information 132  
from maternal and infant medical with permission from 133  
participants. In this proof of concept study, we analyzed paired 134  
maternal-cord serum samples from 30 women. CiOB2 study 135  
protocols were approved by the Institutional Review Boards of 136  
the University of California, San Francisco (13-12160). 137

**Chemical Analysis: Suspect Screening.** *Chemical* 138  
*Suspect Database.* For our maternal/cord paired serum 139  
suspect screening study, we developed a  $\sim 3500$  chemical 140  
suspect database that combined data from an in-house 141  
Environmental Organic Acid (EOA) database we used in our 142  
earlier study<sup>26</sup> with additional high-production chemicals in 143  
the U.S. as described below ([Supporting Information \(SI\)](#) 144  
[Figure S1](#)). 145

1. *In-House Industrial Chemical Database.* Our in-house 146  
chemical database ([SI Figure S1](#)) consists of 714 chemical 147  
entries, including 369 chemicals from our previous published 148  
Environmental Organic Acid (EOA) database,<sup>26</sup> 207 less- 149  
studied per and polyfluoroalkyl substances (PFAS), 44 flame 150  
retardants (FR) including organophosphate flame retardants 151  
(OPFR), 30 quaternary ammonium compounds (QACs), and 152  
64 other industrial chemicals widely used in everyday life (e.g., 153  
plasticizers and over-the-counter medications). 154

2. *High-Production Chemicals Obtained from EPA's* 155  
*Chemical Data Reporting 2016.* We obtained a list of 8707 156  
high-production (average national production volume over 157  
25 000 lbs) chemicals from the U.S. EPA Chemical Data 158  
Reporting (CDR) 2016 database.<sup>12</sup> We queried their CASRN 159  
against the U.S. EPA CompTox Chemicals Dashboard<sup>30</sup> and 160  
kept 4963 chemicals that had molecular formulas. There were 161  
3744 chemicals that were excluded because of unsuccessful 162  
matching of CASRN ( $n = 1370$ ) and no matched molecular 163  
formula (potential mixtures,  $n = 2,374$ ). We further restricted 164  
the Chemical Data Reporting list to include chemicals with 165  
formulas that were also included in the U.S. EPA suspect 166  
screening DSSTox desalted formula list to remove entries that 167  
were not LC amenable (e.g., metals). There were 3,380 168  
Chemical Data Reporting chemicals remaining that corre- 169  
sponded to 2421 unique chemical formulas. 170

The final suspect database included 2421 unique chemical 171  
formulas and 3535 chemical entries after merging the in-house 172  
EOA database and Chemical Data Reporting lists and 173  
removing duplicated entries, chemicals with fewer than 100 174  
units in mass or without formulas (e.g., chemical mixtures), 175  
and chemicals that are only gas-chromatography amenable. 176  
Gas-chromatography amenability was determined by examin- 177  
ing the polarity of the chemicals. If a chemical did not have any 178  
polar groups, such as ROH or ROR, it was removed because it 179  
would not likely ionize in electrospray ionization. Structure 180  
information (SMILES and InChI keys) were obtained from 181  
PubChem search. This database was imported into the Agilent 182  
Mass Hunter Personal Compound Database and Library 183



**Figure 1.** Suspect screen analysis workflow. \*For detailed steps regarding feature extraction and formula matching, please refer to supplementary file (SI Figures S2 and S3). The annotation levels refer to the annotation scheme proposed by Schymanski et al.<sup>31</sup> for communicating confidence.

184 software (PCDL) for downstream suspect screening analysis.  
185 The suspect feature matching was done at the formula level, by  
186 matching an observed MS1 spectrum to theoretical spectra for  
187 MS-Ready formulas in PCDL. It is important to note that  
188 PCDL does not have retention times or reference MS1 or MS2  
189 spectra.


190 **LC-QTOF/MS Analysis.** After compiling the final chemical  
191 suspect database, we performed HPLC/HRMS analysis using  
192 Agilent 1290 UPLC interfaced with Agilent 6550 QTOF/MS  
193 with electrospray ionization (ESI) in positive and negative  
194 mode (Agilent Technologies, Santa Clara, CA), data  
195 processing, data analysis, and compound confirmation with  
196 detailed steps listed below (Figure 1).

197 **1. Chemical Analysis.** Serum samples (250  $\mu$ L) were  
198 extracted by protein precipitation with methanol. Ten  $\mu$ L of  
199 the serum extracts were then injected into the UPLC-QTOF/  
200 MS system. Both negative and positive ionization mode were  
201 studied. Agilent Eclipse Plus C18 (2.1  $\times$  100 mm, 1.8  $\mu$ m)  
202 column was used. Gradient A was made as 5 mM Ammonium  
203 Acetate in water (0.1% methanol). Gradient B was made as 5  
204 mM ammonium acetate in methanol with 10% water. The  
205 gradient flow was set as 0.3 mL/min. The total ion  
206 chromatography (TIC) scan mass range was 100–1000  $m/z$ .  
207 Quality control samples including blanks (LCMS grade water:  
208 Water, Burdick & Jackson for LC-MS, for HPLC, Burdick &  
209 Jackson, LC365-1; serum blank) and in-house laboratory  
210 control samples (matrix spike or LCS) were also analyzed  
211 together within one batch. Two technical replicates were

analyzed for each sample.<sup>32,33</sup> The instrumental parameters are  
presented in the [Supplementary Spreadsheet](#).

212  
213  
214 **2. Quality Assurance/Quality Control.** QA/QC samples  
215 were used to monitor the general performance of the  
216 injections, including retention time shifts, mass accuracy and  
217 peak intensity decay. Perfluoro-*n*-[1,2-<sup>13</sup>C<sub>2</sub>] octanoic acid  
218 (M2PFOA) was used as internal standard in negative  
219 ionization mode; triphenyl phosphate D15 and DL-cotinine  
220 (methyl D3) was used in the positive ionization mode. Blank  
221 samples were used to correct artificial features that might be  
222 introduced during sample preparation by removing features for  
223 which, abundances were no more than two times higher in the  
224 blanks compared to the samples. The blanks were made using  
225 ultraclean water (LCMS grade water: Water, Burdick &  
226 Jackson for HPLC, LC365-1) and the QCs were made using  
227 commercially available human AB serum (Corning Human AB  
228 Serum, 35060CI). QC serum is prepared using human AB  
229 serum spiked with 7 PFAS compounds and 6 OPFR  
230 compounds (SI Tables S2 and S3) (final concentration = 10  
231 ng/mL in QC serum). The blank samples and the QC samples  
232 were treated the same way as the maternal and cord serum  
233 samples (SI Figure S2) following all the steps of the sample  
234 treatment and analysis.

235 For each batch, 10 pairs of maternal and cord matched  
236 serum samples, together with two water blanks, two blank  
237 serum samples, and two QC serum samples were extracted  
238 together and injected together in one batch. The samples were  
239 randomized, but each maternal and cord pair were run in the  
240 same batch to minimize any batch effect between maternal and



**Figure 2.** Steps for prioritizing chemicals of interest based on (1) a high detection frequency (suggesting ubiquitous exposure); (2) disproportionate distribution of peak area (relative concentrations) in fetal versus maternal serum (suggesting potentially different exposure concentration); (3) high correlation in peak area between fetal and maternal serum (suggesting that maternal concentration could be a proxy for fetal exposure); and/or (4) disproportionate distribution of peak area relative concentrations across maternal race/ethnicity or socioeconomic status (suggesting higher exposure to different demographic groups). The prioritized chemical features are then used to match against MS/MS spectral libraries and for confirmation with analytic standards. Abbreviations: DF: detection frequency; C&M: cord and maternal; PA: peak area; CvsM: cord compared to maternal peak area; C-M: cord-maternal; PAR: peak area ratio; Corr: correlation; DEMO: demographic differences; NHANES: National Health and Nutrition Examination Survey.

241 cord samples since we are interested in differences in peak  
242 areas between maternal and cord samples. Every sample was  
243 injected twice (instrumental replicate) to account for  
244 variability in peak areas originating from the instrument.

245 **3. LC-QTOF/MS Data Processing.** The obtained raw data  
246 files were processed following an optimized workflow  
247 described in detail elsewhere.<sup>32,33</sup> The workflow includes  
248 molecular feature extraction (MFE) to extract compound  
249 features across the batch data files and feature alignment using  
250 Agilent Masshunter Profinder software (version B.10.0) to  
251 align all features (identify and combine the same features by  
252 comparing their retention times and spectra) in each batch.  
253 For feature alignment across batches and formula matching we  
254 used Mass Profile Professional software (MPP version  
255 12.06.01). The steps regarding feature extraction and formula  
256 matching is sketched in SI Figure S3. Each batch was  
257 composed of 10 pairs ( $N = 20$  total) plus QC and blank  
258 samples for a total of three batches. After feature alignment, we  
259 kept only feature peaks with intensities at least two times  
260 higher than those in the water blank samples.

The chromatogram peak area, as integrated by the Agilent 261  
MassHunter Profinder software, is used a surrogate for 262  
chemical concentration allowing for comparisons of same 263  
chemical across samples and batches. This approach can only 264  
be used when studying the same chemical across samples and 265  
not when comparing two different chemicals due to potentially 266  
important differences in ionization efficiency. We used R 267  
(version 3.5.1) and Python (version 3.9.2) for our data 268  
processing and data analysis. The processing and analytical 269  
steps were (1) combining features obtained from all three 270  
batches, (2) averaging the peak area of the two technical 271  
replicates, (3) imputing values below the limit of detection, (4) 272  
performing batch correction, and (5) performing downstream 273  
analysis using batch-corrected peak areas. 274

Imputation of values below the limit of detection was 275  
conducted using a computational approach which assigned 276  
missing values based on the distribution of the data points. The 277  
measured abundances were log transformed and for each 278  
chemical across samples we calculated the median, the 279  
minimum and the standard deviation of the distribution. 280

281 After fitting a normal distribution to the data points, the  
282 algorithm then generated random values between the  
283 measured minimum abundance ( $\sim 5000$ ) and the theoretical  
284 minimum (0) following the shape of the distribution. The  
285 algorithm is available on Github ([https://github.com/  
286 dimitriabrahamsson/wangetal\\_maternal\\_cord.git](https://github.com/dimitriabrahamsson/wangetal_maternal_cord.git)).

287 Batch correction was conducted using a software package  
288 called ComBat,<sup>34</sup> which is commonly used in batch effect  
289 corrections in bioinformatics. One advantage of the ComBat  
290 package is that it can be used to correct for batch effect while  
291 preserving other differences across samples and that way  
292 avoiding overcorrection.

293 In addition to MassHunter Profinder, we expanded our MS/  
294 MS searching by employing MS-Dial,<sup>35</sup> which is an open  
295 source software package for analyzing nontargeted analysis  
296 data and has been developed by researchers at University of  
297 California, Davis and the RIKEN Center for Sustainable  
298 Resource Science (Japan).<sup>35</sup> Using the same parameters as for  
299 MassHunter (Supplementary Spreadsheet), we searched the  
300 "All public MS/MS" databases for positive MS/MS (13,303  
301 unique compounds) and for negative MS/MS (12 879 unique  
302 compounds).

303 *Descriptive and Statistical Analysis.* We developed a  
304 workflow which uses descriptive and statistical analysis  
305 methods to prioritize chemical suspects in the large universe  
306 of chemical features that are detected with HRMS for further  
307 analysis. For our prioritization, chemicals of interest were those  
308 with (1) a high detection frequency (suggesting ubiquitous  
309 exposure); (2) disproportionate distribution of peak area  
310 (relative concentrations) in fetal versus maternal serum  
311 (suggesting potentially different exposure concentration); (3)  
312 high correlation in peak area between fetal and maternal serum  
313 (suggesting that maternal concentration could be a proxy for  
314 fetal exposure); and/or (4) disproportionate distribution of  
315 peak area relative concentrations across maternal race/  
316 ethnicity or socioeconomic status (suggesting higher exposure  
317 to different demographic groups). Accordingly, we derived  
318 different measures to evaluate these criteria of interest as  
319 described below.

320 First, we obtained the detection frequencies for the paired  
321 maternal and cord samples ( $DF_{\text{paired}}$ ) as an indicator of how  
322 widespread chemical features may be among pregnant women  
323 and their newborns, ranging from zero to 30.  $DF_{\text{paired}}$  of one  
324 means that the feature was detected in both the maternal and  
325 cord samples obtained from the same participant. We also  
326 ranked the features according to their median peak area across  
327 both maternal and cord samples from largest to smallest peak  
328 area ( $\text{rank}_{\text{PA}}$ ; smaller ranks corresponds to larger peak areas) as  
329 a proxy to identify features that may be of higher abundance.<sup>20</sup>

330 Second, we conducted two assessments of the relationship  
331 between maternal and cord peak areas: (1) the ratios of cord vs  
332 maternal peak areas ( $\text{PAR}_{\text{C vs M}}$ ), and (2) the Spearman  
333 correlation between cord and maternal peak areas ( $\text{Corr}_{\text{C-M}}$ ). A  
334  $\text{PAR}_{\text{C vs M}}$  greater than 1 indicated that the peak area of this  
335 feature was higher in cord serum than in maternal serum,  
336 whereas a value less than 1 means the peak area was higher in  
337 maternal than in cord serum. Features with an absolute  
338  $\text{Corr}_{\text{C-M}}$  value of at least 0.5 and a  $p$ -value of less than 0.05  
339 were considered to have a statistically significant correlation  
340 between cord and maternal peak area.

341 Third, among those chemical features with detection  
342 frequencies of at least 80% in maternal or cord serum samples,  
343 we assessed separately whether the peak areas in cord or

maternal serum samples differed by race/ethnicity, education,  
household income, and nativity (U.S.-born status). Linear  
regression with batch adjustment was used if the log-  
transformed peak area passed the Shapiro normality test ( $p$ -  
value being at least 0.05). Otherwise, logistic regression of the  
highest tertile of the peak area was used, adjusting for batch.  
When there is zero cell for the tabulation of peak area (highest  
tertile vs other) and the demographic variable, nonparametric  
Kruskal–Wallis test was used. A  $p$ -value less than 0.05 was  
considered statistically significant. The statistical analyses on  
the relationship between chemical features and demographic  
variables were not adjusted for multiple comparisons, as the  
main goal was to inform the prioritization of potential suspect  
chemicals.

*Chemical Prioritization Criteria and Steps.* Based on the  
criteria of interest and their corresponding measures, we used  
an iterative four-step approach to prioritize and select  
chemicals for confirmation using reference standards (Figure  
2). We assigned confidence levels to features based on the  
scale developed by Schymanski et al.<sup>31</sup> All features extracted by  
MassHunter Profinder and/or with MS-Dial were at first  
considered level-5 annotations. The features that were assigned  
chemical formulas based on accurate mass, isotope patterns  
and abundance were assigned level-4 identification confidence.  
The ESI adducts that were used for matching formulas were  
 $\text{H}^+$ ,  $\text{Na}^+$ , and  $\text{NH}_4^+$  in positive mode and  $\text{CH}_3\text{COO}^-$  in  
negative mode.

The chemical candidates matched to suspect features by  
formula, and could be annotated with a tentative structure,  
were considered level-3 identification confidence. Due to the  
large variability and uncertainty in the level-3 annotations, we  
developed and applied a scoring algorithm for distinguishing  
between likely accurate and likely inaccurate level 3  
annotations. As a first step, we collected all isomers for a  
given formula that could be found in EPA's CompTox  
Chemicals Dashboard.<sup>30</sup> We then calculated the probability of  
blindly picking the right isomer (called "blind probability") by  
dividing 1 by the number of available isomers. For example, if a  
formula had only 1 available isomer the probability of blindly  
picking the right isomer is 1, whereas if a formula had 100  
available isomers the probability is  $1/100 = 0.01$ . We then  
collected the number of Dashboard data sources, PubChem  
data sources, PubMed publications and CPDAT count for each  
isomer and normalized the data in each column (i.e.,  
Dashboard data sources, PubChem data sources, etc.) from 0  
to 1 for every group of isomers that corresponded to one  
formula. We then calculated the average source score (called  
"source score") for every isomer by taking the average of  
Dashboard, PubChem, PubMed and CPDAT scores. Finally,  
we calculated the overall score by taking the average of the  
blind probability and the source score. We decided to calculate  
the final score this way instead of taking the average of all  
numbers in order to give more weight to blind probability  
instead of the source score. The algorithm is available on  
Github ([https://github.com/dimitriabrahamsson/wangetal\\_  
maternal\\_cord.git](https://github.com/dimitriabrahamsson/wangetal_maternal_cord.git)).

The features, for which there was some evidence to propose  
an exact structure based on experimental MS/MS spectra, or in  
silico MS/MS spectra, were considered level-2 annotations.  
Otherwise, they remained as level-3 or level-4 annotations. For  
a select number of prioritized features, we collected targeted  
MS/MS fragmentation spectra in both positive and negative  
electrospray ionization modes with collision energies of 10 eV, 406

407 20 eV, and 40 eV with a scan rate of four spectra/s and a  
408 retention time window of  $\pm 1$  min. The spectra for all three  
409 collision energies were collected simultaneously. The spectra  
410 were collected following data dependent acquisition (DDA)  
411 and a targeted MS/MS method for the prioritized chemical  
412 features.

413 The acquired spectra were then used to search for potential  
414 matches (at least one fragment peak with mass error  $< 10$  ppm)  
415 in available experimental MS/MS spectral libraries (MS-Dial  
416 databases,<sup>35</sup> MassBank of Europe and North America,<sup>36</sup>  
417 HMDB<sup>37</sup> and mzCloud<sup>38</sup>), and in in silico spectral computa-  
418 tional tools (CFM-ID<sup>39</sup> and MetFrag<sup>40</sup>). For both the  
419 experimental databases and the in silico tools, we searched  
420 compounds for which we could observe a chromatographic  
421 peak for the molecular ion and for peaks which the isotopic  
422 pattern had a score of 70 out of 100 or higher. We then  
423 annotated the observed features with the top candidate ion  
424 suggested by the software's algorithm.

425 Suspect features that were confirmed using a reference  
426 standard with MS, MS/MS and retention time matching were  
427 assigned level-1 confidence in identification.

428 *Step 1.* Based on results from descriptive and statistical  
429 analysis, we selected chemical features that meet the following  
430 criteria (Figure 2):

- 431 a.  $DF_{\text{paired}} = 100\%$
- 432 b. Rank<sub>PA</sub> among the top 50th percentile
- 433 c. Having maternal and cord peak area relationship of  
434 interest: median  $PAR_{C \text{ vs } M} \geq 2$  or median  $PAR_{C \text{ vs } M} \leq$   
435  $0.5$ ; absolute  $Corr_{C-M} \geq 0.5$  ( $p$ -value  $< 0.05$ ). Median  
436  $PAR_{C \text{ vs } M} \geq 2$  means that half of the cord samples had  
437 peak areas at least two times the median peak area  
438 among maternal samples, while median  $PAR_{C \text{ vs } M} \leq 0.5$   
439 means that half of the maternal samples had peak area of  
440 at least two times of the median peak area among cord  
441 samples.
- 442 d. The peak area of cord or maternal samples were different  
443 across at least one demographic variable (race/ethnicity,  
444 education, household income, or nativity).

445 *Step 2.* For chemical features meeting the criteria in step 1,  
446 we merged back the candidate chemical names from our  
447 suspect chemical database based on formula, and then queried  
448 the U.S. EPA's CompTox Chemicals Dashboard<sup>30</sup> by CASRN  
449 to obtain additional information on the candidate chemicals,  
450 including whether they: are biomonitored by NHANES, are  
451 present in various drug lists (e.g., the DrugBank database from  
452 the University of Alberta), have associated ToxCast assay  
453 information, and are on the high production volume list or the  
454 chemical and products database. For the purposes of this  
455 paper, which focuses on exogenous chemicals, we further  
456 prioritized chemicals that were not biomonitored by  
457 NHANES, not pharmaceutical drugs, and not likely to be  
458 endogenous fatty acids (based on chemical structure).  
459 However, there are certain endogenous compounds, such as  
460 cortisol and bile acids, that have shown some associations with  
461 preterm birth in previous studies and might be of interest for  
462 future investigation. For that reason, we included four  
463 endogenous compounds in the prioritized list for MS/MS  
464 spectra matching: cortisol, progesterone, deoxycholic acid, and  
465 chenodeoxycholic acid (three unique formulas; deoxycholic  
466 acid and chenodeoxycholic acid share the same formula).

467 *Step 3.* To increase the likelihood of confirmation with  
468 reference standards given the limited volume of serum samples,

we performed fragmentation analysis by checking the 469  
fragmentation peaks against various sources, including online 470  
experimental databases, such as the MS-Dial databases,<sup>35</sup> 471  
MassBank,<sup>36</sup> and mzCloud,<sup>38</sup> and spectral data generated by 472  
the online in silico fragmentation tools such as CFM-ID.<sup>39</sup> 473  
Chemical features with at least one matched fragment peak 474  
were assigned a level-2 confidence in identification as probable 475  
structures. All the remaining features were assigned a level-4 476  
confidence in identification.<sup>31</sup> 477

*Step 4.* We further conducted confirmation analysis for 478  
chemicals with reference standards that were commercially 479  
available. 480

*Chemical Confirmation Using Reference Standards.* 481  
Among the level-2 identified chemical features with available 482  
reference standards, we confirmed the presence of chemical 483  
features by rerunning the LC-QTOF/MS analysis with their 484  
corresponding reference standard. A suspect feature was 485  
considered confirmed (present in maternal or cord serum) 486  
with level-1 confidence in annotation<sup>31</sup> if it had the same 487  
retention time (RT), accurate mass, and MS/MS spectral 488  
pattern as the LC-QTOF/MS results for the reference 489  
standard. 490

*Database Searching for Previously Reported Structures* 491  
*and Chemical Uses.* After collecting all the structural 492  
information on the detected features, we searched several 493  
databases to collect information on a chemical compound's 494  
reported chemical use and its presence in previous exposure 495  
studies. For this search we used all the chemicals in the top 3 496  
levels of annotation (1–3) as proposed by Schymanski et al.<sup>31</sup> 497  
As a first step, we searched the Human Metabolome 498  
Database<sup>37</sup> to find which compounds were known endogenous 499  
compounds. We then searched EPA's CompTox Chemicals 500  
Dashboard<sup>30</sup> to find which chemicals have known uses as 501  
pharmaceuticals, pesticides, flame retardants, poly/perfluoro- 502  
nated alkyl substances (PFAS), plasticizers, cosmetics, 503  
consumer products, and which chemicals are registered as 504  
high production volume chemicals. Finally, we searched the 505  
Blood Exposome database<sup>41,42</sup> to find which chemicals had 506  
been previously reported in human blood samples in previous 507  
studies. 508

## 509 ■ RESULTS

**Participant Characteristics.** The mean age of participants 510  
was 32 years (SD: 4.7, Table 1). Nearly half of the participants 511  
were Latinas, 37% were non-Hispanic whites, and 17% were 512  
non-Hispanic other race. Around one-third of the pregnant 513  
women were of higher socioeconomic status, with 40% having 514  
some postgraduate education and 30% having an annual 515  
household income  $\geq$  \$125,000. Half of the study participants 516  
were born outside of the U.S., and, on average, had lived in the 517  
U.S. for 22 years. 518

**Suspects by Ionization Modes and Across Maternal** 519  
**Vs Cord Samples.** After data processing, we detected in total 520  
1,450 suspect features (herein referred to as "suspects") that 521  
were matched to 557 unique chemical formulas. Of the 1450 522  
suspect features, we detected 662 suspects in the positive ion 523  
mode and 788 suspects in the negative ion mode, with 282 524  
detected in both ion modes. We observed some limited batch 525  
effect related to how the samples were analyzed in the 526  
instrument (SI Figure S5). Correcting for that effect with 527  
ComBat resulted in small changes in the abundances of the 528  
samples (SI Figure S5). We also observed statistically 529  
significant differences in the abundance of some of the tracers 530

**Table 1. Demographics of the Current Analytical Sample ( $N = 30$  Matched Maternal/Cord Samples)<sup>a</sup>**

characteristics	mean (SD)	$N$ (%)
age	32.4 (4.7)	
race/ethnicity		
Latinas		14 (47)
non-Hispanic whites		11 (37)
non-Hispanic Asians/Pacific Islanders/African Americans		5 (17)
Educational Attainment		
high school/GED or less		11 (37)
some college/AA/College completed		7 (23)
master's or doctoral degree		12 (40)
Household Income		
<\$40,000		12 (40)
\$40,000 – \$124,999		9 (30)
≥\$125,000		9 (30)
Nativity (Born in the U.S.)		
yes		14 (47)
no		15 (50)
DK/NA		1 (3)
years lived in the U.S.	22.0 (12.3)	
Infant Sex		
male		15 (50)
female		15 (50)


<sup>a</sup>Abbreviations: SD: standard deviation; GED: General Education Diploma; AA: Associate in Arts; DK: do not know; NA: not available.

across different batches (SI Figure S6 and S7). Even though these differences are relatively small and only three tracers showed significant differences (SI Figures S6 and S7), we chose to proceed with batch correction to remove any effect related to instrumental variability. This is particularly important for our statistical analyses since we use instrument abundances instead of concentrations, which would control for that effect. Median RT of all detected suspects was 8.9 min (range: 0.9–17.0) and the majority of suspects detected were compounds with mass values of 500 or less (98%).


When looking at the mass accuracy and retention time consistency across batches, the mass errors for the tracer compounds used in positive mode were all below 6 ppm and in negative mode below 5 ppm. The retention times for the tracer compounds in both modes showed only minor shifts approximating 0.2 min in positive mode and 0.3 min in negative mode in the worst cases (SI Tables S2 and S3).

When looking at the differences between maternal and cord samples, 1225 suspects (85%) were detected in at least one paired maternal-cord sample whereas 225 features (15%) were detected in either maternal or cord samples, but not in both pairs. (Figure 3). Three hundred and twenty-eight suspects (23%) were detected in all paired maternal-cord samples. Around half of the suspects (51%) had detection frequencies of 14 or greater among maternal-cord pairs. More suspects with a higher DF in cord relative to maternal samples were found in the negative mode and slightly more suspects with a higher DF in maternal relative to cord samples were found in the positive mode (SI Table S1 and Figure S4 for an overview of the suspects detected in the positive and the negative modes). It is important to note that Figure 3 shows only the features that were present in the suspect list. When looking at all the detected features regardless of their presence in the suspect list, there are approximately 1.5 times more positive ionization features than negative ionization features.


Among these 1225 suspects, the median  $PAR_{C vs M}$  (across all samples for a specific feature) for the 643 suspects detected in the negative mode was 1.1 (IQR: 0.7–1.7) and the median  $PAR_{C vs M}$  among 582 suspects detected in the positive mode was 0.9 (IQR: 0.5–1.5) (Figure 4A). Peak areas in maternal samples were numerically higher relative to the peak areas in cord samples among suspects detected in the positive mode but were numerically lower relative to the peak area in cord samples among suspects detected in the negative mode (Figure 4B). More suspects detected in the negative mode, compared to those in the positive mode, had a median cord peak area at least twice that of the median maternal peak area (median  $PAR_{C vs M} \geq 2$ : 15% vs 10%). On the contrary, more suspects detected in the positive mode, compared to those in the negative mode, had a median maternal peak area that was at least twice that of the median cord peak area (median  $PAR_{C vs M} \leq 0.5$ : 21% vs 10%).



**Figure 3.** Number of suspects by detection frequency among the maternal-cord serum pairs ( $n = 30$ ).



**Figure 4.** Relationship between cord and maternal peak area. A. Distribution of median peak area ratio (cord vs maternal) among 1225 suspects detected in at least 1 paired maternal-cord sample; B. Distribution of median peak area by sample type and ion modes; C. Correlation between cord and maternal peak area among 328 features detected in all maternal-cord pairs.




**Figure 5.** Clustering of suspects (row) in cord and maternal serum whose peak area significantly differed by at least one demographic variable (column).

583 For the 328 suspects detected in all paired samples, we  
 584 further explored the correlation between cord and maternal  
 585 peak area (Figure 4C). There were 104 features with a

Spearman correlation of at least 0.5 and a *p*-value < 0.05. 586  
 Despite that the majority of suspects were detected in at least 587  
 one maternal and one cord sample, 133 suspects (9.2%) were 588





**Figure 6.** Chemical uses information for (A) all annotated compounds and (B) for compounds that were found to not have been previously reported in human exposure studies involving human blood or serum samples. The annotations are shown by confidence level as proposed by Schymanski et al.<sup>31</sup> The chemical use information was collected from databases on EPA's CompTox Chemicals Dashboard.<sup>30</sup> The Human Metabolome Database<sup>37</sup> was used to remove chemical features with endogenous sources. The Blood Exposome database<sup>41,42</sup> was used to determine if a compound had been previously reported in human exposure studies.

589 detected exclusively in maternal or cord serum samples. There  
 590 were 666 suspects in maternal samples and 648 suspects in  
 591 cord samples with detection frequencies of over 80% ( $n = 24$ ).  
 592 Among these, the peak areas of 114 and 102 suspects in  
 593 maternal and cord samples, respectively differed across at least  
 594 one of four demographic variables. There were 99 suspects that  
 595 were detected in all 30 paired samples with peak areas in cord  
 596 or maternal samples that differed across at least one  
 597 demographic variables. Most of the suspects differed by a  
 598 specific demographic variable either when examining maternal  
 599 peak area or cord peak area but not both (Figure 5), suggesting  
 600 that demographic differences in peak area of suspects may vary  
 601 by sample type (maternal versus cord). Among features that  
 602 significantly differed by each corresponding demographic  
 603 variable, more features had a higher median peak area in  
 604 maternal samples among women who were non-Latinas  
 605 (relative to Latinas), had some college education or above  
 606 (relative to those with a high school education or less), had a  
 607 household income of \$40,000 or more (relative to those with a  
 608 household income of less than \$40,000), and were born in the  
 609 U.S. (relative to those who were not). Features' median peak  
 610 area in cord samples showed a similar pattern except that more  
 611 features had a higher median peak area among women who  
 612 were not born in the U.S. (Supplementary Spreadsheet S2).

613 **Features Selected for Fragmentation Analysis.** Based  
 614 on the chemical prioritization criteria and steps described  
 615 above in the Materials and Methods Section (Figure 2), we  
 616 selected 106 suspects detected in positive mode and 102  
 617 suspects (total  $n = 208$ ) detected in negative mode for  
 618 fragmentation analysis (Figure 2). After inspecting the MS/MS  
 619 matches to the MS/MS libraries, we tentatively identified 73  
 620 chemical features (level 2 confidence) (Supplementary  
 621 Spreadsheet: "Level 1–2 annotations").

622 **Confirmed Features.** After purchasing analytical standards  
 623 and comparing the mass spectrum of the detected features and  
 624 that of the corresponding standards, we confirmed the  
 625 presence of 17 chemical features (Supplementary Spreadsheet:

"Level 1–2 annotations"), which came down to 15 unique 626  
 chemical compounds after removing duplicates between 627  
 positive and negative ionization mode (cortisone) and after 628  
 removing stereoisomers (chenodeoxycholic acid) (Supplemen- 629  
 tary Spreadsheet: "Level 1–2 annotations" and "Annotations 630  
 summary"). 631

**Database Search.** When looking at the top scored 632  
 annotations 1, 2, and 3 (score  $\geq 0.5$ ), the largest group, with 633  
 42 annotated compounds, were chemical compounds for 634  
 which there was limited to no available information on their 635  
 chemical uses, their presence in consumer products and 636  
 whether they were high production volume chemicals (Figure 637 f6  
 6 and Supplementary Spreadsheet: "Annotations summary"). 638 f6  
 The majority of these chemicals (33/42) were annotated with 639  
 MS/MS spectral libraries (level 2 annotations). The second 640  
 largest group was plasticizers with 29 compounds. After 641  
 removing the compounds that had been previously reported in 642  
 human exposure studies, we found 55 chemical compounds 643  
 that had not been previously reported. Also, in this case, the 644  
 largest group consisted of chemicals with limited to no 645  
 information (Unknowns;  $n = 37$ ) and the second largest group 646  
 consisted of plasticizers ( $n = 10$ ). We also found four PFAS 647  
 that, according to our method, appeared to not have been 648  
 previously reported in human blood/serum: 4m perfluoro- 649  
 octanesulfonic acid, 6:2 fluorotelomer phosphate monoester, 650  
 methyl perfluoroundecanoate, and 2-perfluorooctyl ethanoic 651  
 acid. However, upon closer examination with literature review, 652  
 we found that only methyl perfluoroundecanoate, and 2- 653  
 perfluorooctyl ethanoic acid had not been previously reported, 654  
 while 4m perfluorooctanesulfonic acid, 6:2 fluorotelomer 655  
 phosphate monoester showed to have been reported in a 656  
 very limited number of studies. 657

## DISCUSSION 658

Suspect screening and nontargeted analysis approaches have 659  
 been increasingly used for both environmental monitor- 660  
 ing<sup>19–21,43–45</sup> and studying human exposure to known and 661

662 unknown chemicals.<sup>25,26,46</sup> However, most studies evaluating  
663 human samples have focused on endogenous compounds and  
664 our study is the first—to our knowledge—that screens for a  
665 comprehensive database of industrial chemicals. Further, we  
666 have additionally expanded analytic capacity through MS/MS  
667 fragmentation analysis in both maternal and cord serum  
668 samples to assist in the identification of chemicals. With our  
669 study of focused screening of matched maternal and cord  
670 serum samples for high production volume industrial  
671 chemicals, our study provides valuable insights on fetal  
672 exposure to previously unreported chemicals.

673 While our study could be described as both “suspect  
674 screening” and “non-targeted analysis”, we chose the  
675 terminology “suspect screening” because it fits better our  
676 focused search of industrial chemicals that are “suspected” to  
677 be present in human blood. In addition, while nontargeted  
678 analysis or untargeted metabolomics studies prioritize features  
679 for MS/MS fragmentation based on detection frequency and  
680 abundance,<sup>22,47,48</sup> we chose to prioritize features that showed  
681 some significance in terms of partitioning between maternal  
682 and cord blood and in terms of demographic variables, shifting  
683 our focus from the most abundant features to exogenous  
684 chemical features that are “suspected” to have some biological  
685 and/or demographic significance. This workflow can be used  
686 for methods prioritizing chemicals for further evaluation and  
687 adds to other approaches for prioritizing the chemical space for  
688 targeted biomonitoring.<sup>13</sup>

689 Following our suspect screening workflow, we found 42  
690 chemical compounds that had limited to no information on  
691 their sources and use and could not be grouped under the  
692 categories of endogenous, pharmaceuticals, pesticides, flame  
693 retardants, PFAS, plasticizers, ingredients in cosmetics and  
694 consumer products or high production volume chemicals, as  
695 classified in EPA’s Chemicals Dashboard.<sup>30</sup> After removing the  
696 chemical compounds that had been previously reported in  
697 human exposure studies, we found 37 chemical compounds  
698 that had limited to no information and could not be grouped in  
699 any of our categories (Figure 6 and Supplemental Spreadsheet:  
700 “Annotations summary” and “Not previously reported”). Some  
701 examples of these chemicals are pyrenophorol, thermopsine,  
702 and thymol-beta-D-glucoside. The identification of chemicals  
703 with unknown sources and uses is likely reflective of gaps in  
704 requirements for disclosing use of chemicals in consumer and  
705 industrial products.<sup>49</sup> Previous work on suspect screening of  
706 chemicals in consumer products has shown that only 30.5% of  
707 the chemicals used in consumer products are reported in  
708 chemical lists with known chemicals used in these  
709 applications.<sup>49</sup>

710 We tentatively identified a number of chemicals that had not  
711 been previously reported in other biomonitoring studies. Some  
712 examples of chemicals with known sources and uses but that  
713 had not been previously reported were (i) 1-(1-acetyl-2,2,6,6-  
714 tetramethylpiperidin-4-yl)-3-dodecylpyrrolidine-2,5-dione,  
715 which is a known high production volume chemical used in  
716 consumer products, such as fragrances; (ii) methyl perfluor-  
717 undecanoate, and 2-perfluorooctyl ethanoic acid, which are  
718 two PFAS; and (iii) Sumilizer GA 80, which is a plasticizer  
719 (Supplemental Spreadsheet: “Not previously reported”). It is  
720 important to note that although our database search for finding  
721 not previously reported chemicals is extensive, it may in some  
722 limited cases produce false positives. As illustrated by two  
723 PFAS (4m perfluorooctanesulfonic acid, 6:2 fluorotelomer  
724 phosphate monoester), there may be cases where less well-

725 studied chemicals may appear as not-previously reported but  
726 they may be reported in human blood/serum by a very limited  
727 number of studies. Nevertheless, these chemicals require  
728 further investigation due to their very limited information in  
729 the literature.

730 The large presence of poorly characterized chemicals in  
731 maternal and cord blood samples warrants further investigation  
732 to understand where these chemicals might be coming from  
733 and how they may affect human health. We found that, in  
734 general, the levels of detected features were similar between  
735 cord and maternal samples (Figures 4A,B), indicating that the  
736 majority of the chemicals observed do not show differential  
737 partitioning between maternal and cord blood and that they  
738 can cross the placenta without being inhibited by filtering  
739 processes. It is important to acknowledge, however, that this  
740 finding could be an artifact of the analytical instrumentation  
741 (LC-QTOF/MS) used in this study, which is primarily focused  
742 on polar and involatile chemicals. Polar chemicals are generally  
743 hydrophilic and dissolve well in blood making it easy for them  
744 to cross the placenta as part of the blood flow from the mother  
745 to the fetus. An additional analysis of the samples with  
746 instruments that focus on nonpolar and volatile/semivolatile  
747 chemicals, such as gas chromatography (GC)-QTOF/MS,  
748 might present a different picture. Nonpolar chemicals may  
749 bind to lipids in the placenta which may slow down their  
750 transfer to the fetus. This is a hypothesis that could be explored  
751 further in future studies.

752 While the majority of chemicals that were detected in  
753 maternal samples were also detected in cord samples, 133  
754 suspects (9.2%) were detected exclusively in maternal or cord  
755 serum samples. This finding indicates that there may be certain  
756 suspects that appear exclusively on the maternal or on the fetal  
757 side. However, it is important to note that the detection  
758 frequency is calculated based on the number of chemicals that  
759 were able to pass the detection threshold of the current  
760 method and that a “non-detect” does not necessarily mean  
761 “non-present.” Thus, a more likely scenario is that these 133  
762 features were present, but at low amounts that could not be  
763 detected with the current analytical method.

764 For several suspect features, we observed significant  
765 differences across socioeconomic and racial/ethnic groups  
766 indicating differential exposures to certain chemical com-  
767 pounds. We observed, for example, that among features that  
768 significantly differed by each corresponding demographic  
769 variable, more features had a higher median peak area in  
770 maternal samples among women with a household income of  
771 \$40,000 or more. This finding could indicate important  
772 socioeconomic differences in the purchase and use of  
773 consumer products. This observation aligns with Montazeri  
774 et al.,<sup>50</sup> in their systematic review of multiple biomonitoring  
775 studies, in which they observed that environmental exposures  
776 are not exclusively associated with lower socioeconomic status,  
777 and that for many environmental contaminants, higher levels  
778 can occur in groups with higher socioeconomic status.

779 We found 23% of the detected features were matched with a  
780 chemical formula from our database (Figure 1). Given that we  
781 focused on high volume chemicals, we anticipated that we  
782 might find more matches. However, many suspects may be of  
783 relatively low concentration in the samples, as are most  
784 industrial chemicals, and in many cases, they may be below the  
785 detection limit of the analytical method. Targeted analysis with  
786 analytical methods of lower mass resolution but higher  
787 sensitivity, such as LC-triple quadrupole MS (LC-TQ/MS),

788 could reveal the presence of additional compounds. This  
789 observation indicates that nontargeted analysis techniques  
790 could benefit from broad screening semitargeted methods,  
791 where hundreds or thousands of analytical standards are used  
792 to screen for specific chemical compounds. Also, there may be  
793 byproducts of metabolism that are generated through the  
794 activation, detoxification and elimination of exogenous  
795 synthetic chemical compounds. These industrial chemical  
796 metabolites can make up a large portion of the human  
797 chemosome of which more than 95% remain unknown or  
798 largely uncharacterized<sup>51–53</sup> and thus are not included in the  
799 current suspect database. Finally, some exposures may not be  
800 present due to biotransformation and metabolism inside  
801 human body. Future studies can consider including predicted  
802 metabolites from environmental chemicals of interest that are  
803 generated by recently developed computational tools such as  
804 the BioTransformer<sup>51</sup> in order to capture exposure to all  
805 possible forms of these chemicals.

806 Our study adds important information to a very scarce body  
807 of literature on suspect screening and nontargeted analysis of  
808 industrial chemical exposures in maternal and fetal pairs. Our  
809 results show that there are potential new chemical exposures  
810 that have not been adequately characterized and have not been  
811 previously of concern for environmental health scientists and  
812 regulators. Our study is an important methodological approach  
813 for future studies that will aim at characterizing the presence  
814 and toxicity of newly detected chemical compounds in the  
815 human body and assess the fate of these compounds in various  
816 human tissues, particularly between the mother and the fetus.  
817 Understanding these exposures and how they may contribute  
818 to adverse health outcomes is crucial in characterizing the  
819 human exposome and eventually preventing the development  
820 of disease.

## 821 ■ ASSOCIATED CONTENT

### 822 ■ Supporting Information

823 The Supporting Information is available free of charge at  
824 <https://pubs.acs.org/doi/10.1021/acs.est.0c05984>.

825 Figures S1–S7 and Tables S1–S3 (PDF)

826 Contains tables, spreadsheets and raw data referenced  
827 throughout the manuscript (XLSX)

## 828 ■ AUTHOR INFORMATION

### 829 Corresponding Author

830 Tracey J. Woodruff – Department of Obstetrics, Gynecology  
831 and Reproductive Sciences, Program on Reproductive Health  
832 and the Environment, University of California, California  
833 94143, United States; Email: [tracey.woodruff@ucsf.edu](mailto:tracey.woodruff@ucsf.edu)

### 834 Authors

835 Aolin Wang – Department of Obstetrics, Gynecology and  
836 Reproductive Sciences, Program on Reproductive Health and  
837 the Environment, University of California, California 94143,  
838 United States

839 Dimitri Panagopoulos Abrahamsson – Department of  
840 Obstetrics, Gynecology and Reproductive Sciences, Program  
841 on Reproductive Health and the Environment, University of  
842 California, California 94143, United States; [orcid.org/0000-0002-3402-7565](https://orcid.org/0000-0002-3402-7565)

844 Ting Jiang – California Environmental Protection Agency,  
845 Department of Toxic Substances Control, Environmental

Chemistry Laboratory, Berkeley, California 94710, United States 846

Miaomiao Wang – California Environmental Protection Agency, Department of Toxic Substances Control, Environmental Chemistry Laboratory, Berkeley, California 94710, United States 847–849

Rachel Morello-Frosch – Department of Environmental Science, Policy and Management and School of Public Health, University of California, Berkeley, Berkeley, California 94710, United States 850–853

June-Soo Park – California Environmental Protection Agency, Department of Toxic Substances Control, Environmental Chemistry Laboratory, Berkeley, California 94710, United States 854–857

Marina Sirota – Bakar Computational Health Sciences Institute and Department of Pediatrics, University of California, San Francisco, California 94158, United States 858–861

Complete contact information is available at: <https://pubs.acs.org/10.1021/acs.est.0c05984> 862–864

### 865 Author Contributions

+These two authors contributed equally 866

### 867 Notes

The authors declare no competing financial interest. 868

## 869 ■ ACKNOWLEDGMENTS

This study was funded by NIH/NIEHS grant numbers P30-ES030284, UG3OD023272, UH3OD023272, P01ES022841, R01ES027051 and by the U.S. EPA grant number RD83543301. We thank Courtney Cooper for assistance with the manuscript preparation, language editing, and proof reading. All raw data and spectra was submitted to the Metabolomics Workbench (<https://www.metabolomicsworkbench.org/>). 870–877

## 878 ■ REFERENCES

- (1) Diamanti-Kandarakis, E.; Bourguignon, J.-P.; Giudice, L. C.; Hauser, R.; Prins, G. S.; Soto, A. M.; Zoeller, R. T.; Gore, A. C. Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement. *Endocr. Rev.* **2009**, *30* (4), 293–342. 879–882
- (2) National Cancer Institute. *Reducing Environmental Cancer Risk: What We Can. Do Now. President's Cancer Panel 2008- 2009 Annual Report.*; Bethesda, MD, 2010. 883–885
- (3) The American College of Obstetricians and Gynecologists. Exposure to Toxic Environmental Agents. Committee Opinion No. 575. *Obstet. Gynecol.* **2013**, *122* (4), 931–935. 886–888
- (4) Wang, A.; Padula, A.; Sirota, M.; Woodruff, T. J. Environmental Influences on Reproductive Health: The Importance of Chemical Exposures. *Fertil. Steril.* **2016**, *106* (4), 905–929. 889–891
- (5) Woodruff, T. J.; Zota, A. R.; Schwartz, J. M. Environmental Chemicals in Pregnant Women in the United States: NHANES 2003–2004. *Environ. Health Perspect.* **2011**, *119* (6), 878–885. 892–894
- (6) U.S. Centers for Disease Control and Prevention. The Fourth National Report on Human Exposure to Environmental Chemicals (Updated Tables, January 2017), 2017. 895–897
- (7) Needham, L. L.; Grandjean, P.; Heinow, B.; Jørgensen, P. J.; Nielsen, F.; Patterson, D. G.; Sjödin, A.; Turner, W. E.; Weihe, P. Partition of Environmental Chemicals between Maternal and Fetal Blood and Tissues. *Environ. Sci. Technol.* **2011**, *45* (3), 1121–1126. 898–901
- (8) Aylward, L. L.; Hays, S. M.; Kirman, C. R.; Marchitti, S. A.; Kenneke, J. F.; English, C.; Mattison, D. R.; Becker, R. A. Relationships of Chemical Concentrations in Maternal and Cord Blood: A Review of Available Data. *J. Toxicol. Environ. Health, Part B* **2014**, *17* (3), 175–203. 902–906

- 907 (9) Morello-Frosch, R.; Cushing, L. J.; Jesdale, B. M.; Schwartz, J.  
908 M.; Guo, W.; Guo, T.; Wang, M.; Harwani, S.; Petropoulou, S.-S. E.;  
909 Duong, W.; Park, J. J.; Petreas, M. X.; Gajek, R.; Alvaran, J.; She, J.;  
910 Dobraca, D.; Das, R.; Woodruff, T. J. Environmental Chemicals in an  
911 Urban Population of Pregnant Women and Their Newborns from San  
912 Francisco. *Environ. Sci. Technol.* **2016**, *50* (22), 12464–12472.
- 913 (10) U.S. Environmental Protection Agency. Chemical Data  
914 Reporting Fact Sheet: Basic Information [https://www.epa.gov/  
915 chemical-data-reporting/chemical-data-reporting-fact-sheet-basic-  
916 information](https://www.epa.gov/chemical-data-reporting/chemical-data-reporting-fact-sheet-basic-information) (accessed 2017/6/19).
- 917 (11) Di Renzo, G. C.; Conry, J. A.; Blake, J.; DeFrancesco, M. S.;  
918 DeNicola, N.; Martin, J. N.; McCue, K. A.; Richmond, D.; Shah, A.;  
919 Sutton, P.; Woodruff, T. J.; van der Poel, S. Z.; Giudice, L. C.  
920 International Federation of Gynecology and Obstetrics Opinion on  
921 Reproductive Health Impacts of Exposure to Toxic Environmental  
922 Chemicals. *Int. J. Gynecol. Obstet.* **2015**, *131* (3), 219–225.
- 923 (12) U.S. Environmental Protection Agency. 2016 Chemical Data  
924 Reporting Results [https://www.epa.gov/chemical-data-reporting/  
925 2016-chemical-data-reporting-results](https://www.epa.gov/chemical-data-reporting/2016-chemical-data-reporting-results) (accessed 2017/7/22).
- 926 (13) Pellizzari, E. D.; Woodruff, T. J.; Boyles, R. R.; Kannan, K.;  
927 Beamer, P. I.; Buckley, J. P.; Wang, A.; Zhu, Y.; Bennett, D. H.  
928 (Environmental influences on Child Health Outcomes). Identifying  
929 and Prioritizing Chemicals with Uncertain Burden of Exposure:  
930 Opportunities for Biomonitoring and Health-Related Research.  
931 *Environ. Health Perspect.* **2019**, *127* (12), 126001.
- 932 (14) Andra, S. S.; Austin, C.; Patel, D.; Dolios, G.; Awawda, M.;  
933 Arora, M. Trends in the Application of High-Resolution Mass  
934 Spectrometry for Human Biomonitoring: An Analytical Primer to  
935 Studying the Environmental Chemical Space of the Human  
936 Exposome. *Environ. Int.* **2017**, *100*, 32–61.
- 937 (15) Dennis, K. K.; Marder, E.; Balshaw, D. M.; Cui, Y.; Lynes, M.  
938 A.; Patti, G. J.; Rappaport, S. M.; Shaughnessy, D. T.; Vrijheid, M.;  
939 Barr, D. B. Biomonitoring in the Era of the Exposome. *Environ. Health  
940 Perspect.* **2017**, *125* (4). DOI: 10.1289/EHP474.
- 941 (16) Wambaugh, J. F.; Bare, J. C.; Carignan, C. C.; Dionisio, K. L.;  
942 Dodson, R. E.; Jolliet, O.; Liu, X.; Meyer, D. E.; Newton, S. R.;  
943 Phillips, K. A.; Price, P. S.; Ring, C. L.; Shin, H.-M.; Sobus, J. R.; Tal,  
944 T.; Ulrich, E. M.; Vallero, D. A.; Wetmore, B. A.; Isaacs, K. K. New  
945 Approach Methodologies for Exposure Science. *Current Opinion in  
946 Toxicology* **2019**, *15*, 76–92.
- 947 (17) Walker, D. I.; Valvi, D.; Rothman, N.; Lan, Q.; Miller, G. W.;  
948 Jones, D. P. The Metabolome: A Key Measure for Exposome  
949 Research in Epidemiology. *Current Epidemiology Reports* **2019**, *6* (2),  
950 93–103.
- 951 (18) Gerona, R. R.; Schwartz, J. M.; Pan, J.; Friesen, M. M.; Lin, T.;  
952 Woodruff, T. J. Suspect Screening of Maternal Serum to Identify New  
953 Environmental Chemical Biomonitoring Targets Using Liquid  
954 Chromatography-Quadrupole Time-of-Flight Mass Spectrometry. *J.  
955 Exposure Sci. Environ. Epidemiol.* **2018**, *28* (2), 101–108.
- 956 (19) Newton, S. R.; McMahan, R. L.; Sobus, J. R.; Mansouri, K.;  
957 Williams, A. J.; McEachran, A. D.; Strynar, M. J. Suspect Screening  
958 and Non-Targeted Analysis of Drinking Water Using Point-of-Use  
959 Filters. *Environ. Pollut.* **2018**, *234*, 297–306.
- 960 (20) Rager, J. E.; Strynar, M. J.; Liang, S.; McMahan, R. L.; Richard,  
961 A. M.; Grulke, C. M.; Wambaugh, J. F.; Isaacs, K. K.; Judson, R.;  
962 Williams, A. J.; Sobus, J. R. Linking High Resolution Mass  
963 Spectrometry Data with Exposure and Toxicity Forecasts to Advance  
964 High-Throughput Environmental Monitoring. *Environ. Int.* **2016**, *88*,  
965 269–280.
- 966 (21) Wang, Y.; Yu, N.; Zhu, X.; Guo, H.; Jiang, J.; Wang, X.; Shi, W.;  
967 Wu, J.; Yu, H.; Wei, S. Suspect and Nontarget Screening of Per- and  
968 Polyfluoroalkyl Substances in Wastewater from a Fluorochemical  
969 Manufacturing Park. *Environ. Sci. Technol.* **2018**, *52* (19), 11007–  
970 11016.
- 971 (22) Moschet, C.; Anumol, T.; Lew, B. M.; Bennett, D. H.; Young,  
972 T. M. Household Dust as a Repository of Chemical Accumulation:  
973 New Insights from a Comprehensive High-Resolution Mass  
974 Spectrometric Study. *Environ. Sci. Technol.* **2018**, *52* (5), 2878–2887.
- (23) Tautenhahn, R.; Cho, K.; Uritboonthai, W.; Zhu, Z.; Patti, G. 975  
976 J.; Szuздak, G. An Accelerated Workflow for Untargeted Metab-  
977 olics Using the METLIN Database. *Nat. Biotechnol.* **2012**, *30* (9),  
978 826–828.
- (24) Petrick, L. M.; Schiffman, C.; Edmands, W. M. B.; Yano, Y.; 979  
980 Perttula, K.; Whitehead, T.; Metayer, C.; Wheelock, C. E.; Arora, M.;  
981 Grigoryan, H.; Carlsson, H.; Dudoit, S.; Rappaport, S. M. 982  
983 Metabolomics of Neonatal Blood Spots Reveal Distinct Phenotypes  
984 of Pediatric Acute Lymphoblastic Leukemia and Potential Effects of  
985 Early-Life Nutrition. *Cancer Lett.* **2019**, *452*, 71–78.
- (25) Grashow, R.; Bessonneau, V.; Gerona, R. R.; Wang, A.; 985  
986 Trowbridge, J.; Lin, T.; Buren, H.; Rudel, R. A.; Morello-Frosch, R.  
987 Integrating Exposure Knowledge and Serum Suspect Screening as a  
988 New Approach to Biomonitoring: An Application in Firefighters and  
989 Office Workers. *Environ. Sci. Technol.* **2020**, *54* (7), 4344–4355.
- (26) Wang, A.; Gerona, R. R.; Schwartz, J. M.; Lin, T.; Sirota, M.; 990  
991 Morello-Frosch, R.; Woodruff, T. J. A Suspect Screening Method for  
992 Characterizing Multiple Chemical Exposures among a Demographi-  
993 cally Diverse Population of Pregnant Women in San Francisco. 994  
995 *Environ. Health Perspect.* **2018**, *126* (7), 077009.
- (27) Wang, A.; Schwartz, J. M.; Gerona, R.; Lin, T.; Morello-Frosch, 995  
996 R.; Sirota, M.; Woodruff, T. The Pregnancy Chemisome in Relation  
997 to Birth Outcomes and Consumer Product Use: Suspect Screening of  
998 Industrial Chemicals. *ISEE Conference Abstracts 2018*, *2018* (1) 999  
1000 DOI: 10.1289/isesee.2018.O03.03.11.
- (28) Wild, C. P. Complementing the Genome with an “Exposome”: 1000  
1001 The Outstanding Challenge of Environmental Exposure Measurement  
1002 in Molecular Epidemiology. *Cancer Epidemiol., Biomarkers Prev.* **2005**,  
1003 *14* (8), 1847–1850.
- (29) Wang, Z.; Dewitt, J. C.; Higgins, C. P.; Cousins, I. T. A Never- 1004  
1005 Ending Story of Per- and Polyfluoroalkyl Substances (PFASs)?  
1006 *Environ. Sci. Technol.* **2017**, *51*, 2508–2518.
- (30) U.S. Environmental Protection Agency. Chemistry Dashboard 1007  
1008 <https://comptox.epa.gov/dashboard/>.
- (31) Schymanski, E. L.; Jeon, J.; Gulde, R.; Fenner, K.; Ruff, M.; 1009  
1010 Singer, H. P.; Hollender, J. Identifying Small Molecules via High  
1011 Resolution Mass Spectrometry: Communicating Confidence. *Environ.  
1012 Sci. Technol.* **2014**, *48* (4), 2097–2098.
- (32) Houtz, E.; Wang, M.; Park, J.-S. Identification and Fate of 1013  
1014 Aqueous Film Forming Foam Derived Per- and Polyfluoroalkyl  
1015 Substances in a Wastewater Treatment Plant. *Environ. Sci. Technol.*  
1016 **2018**, *52* (22), 13212–13221.
- (33) Wang, M.; Bastiaensen, M.; Kinyua, J.; Petreas, M.; Covaci, A.; 1017  
1018 Park, J.-S. Exposure Profile Comparison and Screening of Unknown  
1019 Contaminants Using LC-QToF: A Cat Hyperthyroidism Study.  
1020 *Dioxin 2019*: Kyoto, Japan, 2019.
- (34) Leek, J. T.; Johnson, W. E.; Parker, H. S.; Jaffe, A. E.; Storey, J. 1021  
1022 D. The Sva Package for Removing Batch Effects and Other Unwanted  
1023 Variation in High-Throughput Experiments. *Bioinformatics* **2012**, *28*  
1024 (6), 882–883.
- (35) CompMS | MS-DIAL [http://prime.psc.riken.jp/compms/  
1025 msdial/main.html#Demonstration](http://prime.psc.riken.jp/compms/msdial/main.html#Demonstration) (accessed 2020/5/19). 1026
- (36) Horai, H.; Arita, M.; Kanaya, S.; Nihei, Y.; Ikeda, T.; Suwa, K.; 1027  
1028 Ojima, Y.; Tanaka, K.; Tanaka, S.; Aoshima, K.; Oda, Y.; Kakazu, Y.;  
1029 Kusano, M.; Tohge, T.; Matsuda, F.; Sawada, Y.; Hirai, M. Y.;  
1030 Nakanishi, H.; Ikeda, K.; Akimoto, N.; Maoka, T.; Takahashi, H.; Ara,  
1031 T.; Sakurai, N.; Suzuki, H.; Shibata, D.; Neumann, S.; Iida, T.;  
1032 Tanaka, K.; Funatsu, K.; Matsuura, F.; Soga, T.; Taguchi, R.; Saito, K.;  
1033 Nishioka, T. MassBank: A Public Repository for Sharing Mass  
1034 Spectral Data for Life Sciences. *J. Mass Spectrom.* **2010**, *45* (7), 703–  
1035 714.
- (37) Wishart, D. S.; Feunang, Y. D.; Marcu, A.; Guo, A. C.; Liang, 1036  
1037 K.; Vázquez-Fresno, R.; Sajed, T.; Johnson, D.; Li, C.; Karu, N.;  
1038 Sayeeda, Z.; Lo, E.; Assempour, N.; Berjanskii, M.; Singhal, S.; Arndt,  
1039 D.; Liang, Y.; Badran, H.; Grant, J.; Serra-Cayuela, A.; Liu, Y.;  
1040 Mandal, R.; Neveu, V.; Pon, A.; Knox, C.; Wilson, M.; Manach, C.;  
1041 Scalbert, A. HMDB 4.0: The Human Metabolome Database for 2018. 1042  
1043 *Nucleic Acids Res.* **2018**, *46* (D1), D608–D617.

- 1043 (38) mzCloud - Advanced Mass Spectral Database <https://www.mzcloud.org/>.
- 1044 (39) Allen, F.; Pon, A.; Wilson, M.; Greiner, R.; Wishart, D. CFM-  
1046 ID: A Web Server for Annotation, Spectrum Prediction and  
1047 Metabolite Identification from Tandem Mass Spectra. *Nucleic Acids*  
1048 *Res.* **2014**, *42* (W1), W94–W99.
- 1049 (40) Ruttkies, C.; Schymanski, E. L.; Wolf, S.; Hollender, J.;  
1050 Neumann, S. MetFrag Relaunched: Incorporating Strategies beyond  
1051 in Silico Fragmentation. *J. Cheminf.* **2016**, *8*, 3.
- 1052 (41) Barupal, D. K.; Fiehn, O. Generating the Blood Exposome  
1053 Database Using a Comprehensive Text Mining and Database Fusion  
1054 Approach. *Environ. Health Perspect.* **2019**, *127* (9) 097008.  
1055 DOI: [10.1289/EHP4713](https://doi.org/10.1289/EHP4713).
- 1056 (42) The Blood Exposome Database [https://bloodexposome.org/](https://bloodexposome.org/#/dashboard)  
1057 [#/dashboard](https://bloodexposome.org/#/dashboard) (accessed 2020/11/17).
- 1058 (43) Ccancapa-Cartagena, A.; Pico, Y.; Ortiz, X.; Reiner, E. J.  
1059 Suspect, Non-Target and Target Screening of Emerging Pollutants  
1060 Using Data Independent Acquisition: Assessment of a Mediterranean  
1061 River Basin. *Sci. Total Environ.* **2019**, *687*, 355–368.
- 1062 (44) Shin, H.; Moschet, C.; Young, T. M.; Bennett, D. H. Measured  
1063 Concentrations of Consumer Product Chemicals in California House  
1064 Dust: Implications for Sources, Exposure, and Toxicity Potential.  
1065 *Indoor Air* **2020**, *30* (1), 60–75.
- 1066 (45) Yu, N.; Guo, H.; Yang, J.; Jin, L.; Wang, X.; Shi, W.; Zhang, X.;  
1067 Yu, H.; Wei, S. Non-Target and Suspect Screening of Per- and  
1068 Polyfluoroalkyl Substances in Airborne Particulate Matter in China.  
1069 *Environ. Sci. Technol.* **2018**, *52* (15), 8205–8214.
- 1070 (46) Plassmann, M. M.; Brack, W.; Krauss, M. Extending Analysis of  
1071 Environmental Pollutants in Human Urine towards Screening for  
1072 Suspected Compounds. *Journal of Chromatography A* **2015**, *1394*,  
1073 18–25.
- 1074 (47) Zhou, B.; Xiao, J. F.; Resson, H. W. Prioritization of Putative  
1075 Metabolite Identifications in LC-MS/MS Experiments Using a  
1076 Computational Pipeline. *Proteomics* **2013**, *13* (2), 248–260.
- 1077 (48) Hohrenk, L. L.; Vosough, M.; Schmidt, T. C. Implementation  
1078 of Chemometric Tools To Improve Data Mining and Prioritization in  
1079 LC-HRMS for Nontarget Screening of Organic Micropollutants in  
1080 Complex Water Matrixes. *Anal. Chem.* **2019**, *91* (14), 9213–9220.
- 1081 (49) Phillips, K. A.; Yau, A.; Favela, K. A.; Isaacs, K. K.; McEachran,  
1082 A.; Grulke, C.; Richard, A. M.; Williams, A. J.; Sobus, J. R.; Thomas,  
1083 R. S.; Wambaugh, J. F. Suspect Screening Analysis of Chemicals in  
1084 Consumer Products. *Environ. Sci. Technol.* **2018**, *52* (5), 3125–3135.
- 1085 (50) Montazeri, P.; Thomsen, C.; Casas, M.; de Bont, J.; Haug, L. S.;  
1086 Maitre, L.; Papadopoulou, E.; Sakhi, A. K.; Slama, R.; Saulnier, P. J.;  
1087 Urquiza, J.; Grazuleviciene, R.; Andrusaityte, S.; McEachan, R.;  
1088 Wright, J.; Chatzi, L.; Basagaña, X.; Vrijheid, M. Socioeconomic  
1089 Position and Exposure to Multiple Environmental Chemical  
1090 Contaminants in Six European Mother-Child Cohorts. *Int. J. Hyg.*  
1091 *Environ. Health* **2019**, *222* (5), 864–872.
- 1092 (51) Djoumbou-Feunang, Y.; Fiamoncini, J.; Gil-De-La-Fuente, A.;  
1093 Greiner, R.; Manach, C.; Wishart, D. S. BioTransformer: A  
1094 Comprehensive Computational Tool for Small Molecule Metabolism  
1095 Prediction and Metabolite Identification. *J. Cheminf.* **2019**, *11* (1), 2.
- 1096 (52) Uppal, K.; Walker, D. I.; Liu, K.; Li, S.; Go, Y.-M.; Jones, D. P.  
1097 Computational Metabolomics: A Framework for the Million  
1098 Metabolome. *Chem. Res. Toxicol.* **2016**, *19–29* (12), 1956–1975.
- 1099 (53) Wishart, D. S.; Feunang, Y. D.; Marcu, A.; Guo, A. C.; Liang,  
1100 K.; Vázquez-Fresno, R.; Sajed, T.; Johnson, D.; Li, C.; Karu, N.;  
1101 Sayeeda, Z.; Lo, E.; Assempour, N.; Berjanskii, M.; Singhal, S.; Arndt,  
1102 D.; Liang, Y.; Badran, H.; Grant, J.; Serra-Cayuela, A.; Liu, Y.;  
1103 Mandal, R.; Neveu, V.; Pon, A.; Knox, C.; Wilson, M.; Manach, C.;  
1104 Scalbert, A. HMDB 4.0: The Human Metabolome Database for 2018.  
1105 *Nucleic Acids Res.* **2018**, *46* (D1), D608–D617.